M&A Deal Summary

Aviragen Therapeutics Acquires Nabi Biopharmaceuticals

On October 30, 2012, Aviragen Therapeutics acquired life science company Nabi Biopharmaceuticals for 100M USD

Acquisition Highlights
  • This is Aviragen Therapeutics’ 1st transaction in the Life Science sector.
  • This is Aviragen Therapeutics’ largest (disclosed) transaction.
  • This is Aviragen Therapeutics’ 1st transaction in the United States.
  • This is Aviragen Therapeutics’ 1st transaction in Maryland.

M&A Deal Summary
Date 2012-10-30
Target Nabi Biopharmaceuticals
Sector Life Science
Buyer(s) Aviragen Therapeutics
Deal Type Add-on Acquisition
Deal Value 100M USD

Target

Nabi Biopharmaceuticals

Rockville, Maryland, United States
Nabi Biopharmaceuticals (NABI) has a broad product portfolio that modulates the immune system. Their research focuses on developing and commercializing novel vaccines and antibody-based therapies that prevent and treat infectious, autoimmune and addictive diseases, such as Staphylococcus aureus and hepatitis infections, and nicotine addiction.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aviragen Therapeutics

Alpharetta, Georgia, United States
Category Company
Sector Life Science
Employees19
DESCRIPTION

Aviragen Therapeutics, Inc. is a developer of innovative products for the prevention and treatment of serious and potentially life-threatening infectious diseases.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
State (Maryland) 1 of 1
Country (United States) 1 of 1
Year (2012) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-06-03 Anaconda Pharma SAS

Paris, France

Anaconda Pharma SAS is a biotechnology company.

Buy -
Mergr

Product

Company

Legal